CL2020002959A1 - Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa. - Google Patents

Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.

Info

Publication number
CL2020002959A1
CL2020002959A1 CL2020002959A CL2020002959A CL2020002959A1 CL 2020002959 A1 CL2020002959 A1 CL 2020002959A1 CL 2020002959 A CL2020002959 A CL 2020002959A CL 2020002959 A CL2020002959 A CL 2020002959A CL 2020002959 A1 CL2020002959 A1 CL 2020002959A1
Authority
CL
Chile
Prior art keywords
hydrolase
aging
leukotriene
modulators
treatment
Prior art date
Application number
CL2020002959A
Other languages
English (en)
Inventor
Eva Czirr
Meghan Kerrisk Campbell
Balazs Szoke
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of CL2020002959A1 publication Critical patent/CL2020002959A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen métodos y composiciones para tratar y/o prevenir afecciones relacionadas con el envejecimiento. Las composiciones usadas en los métodos incluyen inhibidores o antagonistas de la leucotrieno A4 hidrolasa (“LTA4H”) con eficacia en el tratamiento y/o prevención de afecciones relacionadas con el envejecimiento tales como trastornos neurocognitivos.
CL2020002959A 2018-05-15 2020-11-13 Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa. CL2020002959A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671882P 2018-05-15 2018-05-15
US201862694921P 2018-07-06 2018-07-06

Publications (1)

Publication Number Publication Date
CL2020002959A1 true CL2020002959A1 (es) 2021-04-30

Family

ID=68532681

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002959A CL2020002959A1 (es) 2018-05-15 2020-11-13 Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.

Country Status (15)

Country Link
US (3) US11426399B2 (es)
EP (1) EP3793602A4 (es)
JP (2) JP2021529156A (es)
KR (1) KR20200144125A (es)
CN (1) CN112469439A (es)
AU (1) AU2019271122A1 (es)
BR (1) BR112020023001A2 (es)
CA (1) CA3097083A1 (es)
CL (1) CL2020002959A1 (es)
CO (1) CO2020014100A2 (es)
IL (1) IL277927A (es)
MX (1) MX2020011114A (es)
MY (1) MY198220A (es)
SG (1) SG11202010115RA (es)
WO (1) WO2019222265A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY198220A (en) * 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
CN111620942B (zh) * 2020-06-12 2021-10-15 中国科学院昆明动物研究所 布氏鼠耳蝠白三烯A4水解酶抑制剂Motistin的成熟肽及其应用
AU2022376563A1 (en) 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases
WO2026006909A1 (en) * 2024-07-02 2026-01-08 Intelgenx Corp. Method for improving cognition in alzheimer's disease patient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
WO2004029237A1 (en) 2002-09-30 2004-04-08 Bayer Healthcare Ag Splice-variants of the human leukotriene a-4 hydrolase
WO2005027886A2 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
JPWO2005011736A1 (ja) * 2003-07-30 2006-09-14 株式会社 東北テクノアーチ アルツハイマー病の予防および／または治療剤
LT1976828T (lt) * 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US20090069444A1 (en) * 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
US8278302B2 (en) 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
CN101874798B (zh) * 2010-06-29 2012-08-29 北京大学 白三烯a4水解酶与环氧合酶的双功能抑制剂及其用途
UA109290C2 (uk) 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
WO2013138568A1 (en) 2012-03-16 2013-09-19 Vitae Pharmaceuticals, Inc. Liver x reception modulators
US8680280B2 (en) 2012-04-02 2014-03-25 Boehringer Ingelheim International Gmbh Process for the manufacturing of CRR inhibitors
US20130261153A1 (en) 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
AU2014249168B2 (en) * 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022864A8 (pt) * 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
NZ720949A (en) * 2013-12-09 2019-03-29 Univ Leland Stanford Junior Methods and compositions for treating aging-associated conditions
NZ719169A (en) 2013-12-20 2018-08-31 Novartis Ag Heteroaryl butanoic acid derivatives as lta4h inhibitors
CN105891495B (zh) * 2014-11-19 2017-12-05 赤峰学院 5‑脂氧合酶通路蛋白联合预测食管癌患者预后试剂盒
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
EP3995141B1 (en) 2016-04-28 2024-01-03 Alkahest, Inc. Plasma fractions as therapy for thymic cancer
LT3484502T (lt) 2016-08-18 2021-12-10 Alkahest, Inc. Kraujo plazmos frakcijos, kaip su senėjimu susijusio pažinimo sutrikimo gydymo priemonė
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CN110636844A (zh) 2017-04-05 2019-12-31 万能溶剂有限公司 使用ccr3-抑制剂治疗衰老相关损伤的方法及组合物
MX2019012795A (es) 2017-04-26 2020-02-13 Alkahest Inc Régimen de dosificación para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre.
CN111343983A (zh) 2017-10-13 2020-06-26 万能溶剂有限公司 使用ccr3抑制剂治疗瘙痒、干燥症和相关疾病的方法和组合物
MY198220A (en) * 2018-05-15 2023-08-14 Alkahest Inc Treatment Of Aging-Associated Disease With Modulators Of Leukotriene A4 Hydrolase
AU2022376563A1 (en) * 2021-11-01 2023-12-07 Alkahest, Inc. Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases

Also Published As

Publication number Publication date
US11344542B2 (en) 2022-05-31
US20190350917A1 (en) 2019-11-21
JP2024150550A (ja) 2024-10-23
US20200368220A1 (en) 2020-11-26
WO2019222265A1 (en) 2019-11-21
JP2021529156A (ja) 2021-10-28
IL277927A (en) 2020-11-30
SG11202010115RA (en) 2020-11-27
MX2020011114A (es) 2021-01-29
MY198220A (en) 2023-08-14
CN112469439A (zh) 2021-03-09
KR20200144125A (ko) 2020-12-28
BR112020023001A2 (pt) 2021-02-02
US20220226304A1 (en) 2022-07-21
AU2019271122A1 (en) 2020-11-12
US11426399B2 (en) 2022-08-30
EP3793602A1 (en) 2021-03-24
EP3793602A4 (en) 2022-04-20
CO2020014100A2 (es) 2020-11-30
CA3097083A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
CL2020002959A1 (es) Tratamiento de enfermedades asociadas con el envejecimiento con moduladores de la leucotrieno a4 hidrolasa.
CO2021000151A2 (es) Inhibidores de pd-1/pd-l1
MX2021013662A (es) Inhibidores de la autofagia de heteroarilaminopirimidina amida y metodos de uso de estos.
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
MX2021010198A (es) Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
CO2020013762A2 (es) Compuestos dirigidos a brm y métodos de uso asociados
MX2019001718A (es) Fracciones de plasma sanguineo como tratamiento para trastornos cognitivos asociados con el envejecimiento.
CR20210592A (es) Moduladores de la vía integrada del estrés
MX2024000349A (es) Compuestos y usos de los mismos.
NI201800008A (es) Inhibidores peptídicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias
EA201990257A1 (ru) Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
MY197631A (en) Formulations of (r)-2-amino-3-phenylpropyl carbamate
EP4272834A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
CL2021000650A1 (es) Moduladores de la expresión de pnpla3
ECSP20082339A (es) Moduladores de la expresión de apol1
EP4041209A4 (en) TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2021001471A (es) Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4).
CO2019009932A2 (es) Inhibidores duales de magl y faah
CO2022000214A2 (es) Composiciones para el tratamiento de la pérdida del cabello
SG11202104053TA (en) Compositions and methods for the treatment of estrogen-dependent disorders
MX2022000646A (es) Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms).
MX2024006769A (es) Compuestos y usos de los mismos.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
PY1949665A (es) Derivados de tiofeno para el tratamiento de trastornos causados por IgE